Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome

Allogeneic hematopoietic stem cell transplant (AHSCT) outcomes data of older AML/myelodysplastic syndrome (MDS) patients are limited. We retrospectively evaluated consecutive patients ⩾60 years old with AML/MDS who underwent AHSCT between January 2005 and December 2014. The primary objectives were t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2017-11, Vol.52 (11), p.1530-1536
Hauptverfasser:	Modi, D, Deol, A, Kim, S, Ayash, L, Alavi, A, Ventimiglia, M, Bhutani, D, Ratanatharathorn, V, Uberti, J P
Format:	Artikel
Sprache:	eng
Schlagworte:	631/532/1542 631/67/71 Acute myelocytic leukemia Age Age Factors Aged Bone marrow Care and treatment Cell Biology Chemotherapy Confidence intervals Diagnosis Disease-Free Survival Graft vs Host Disease Graft-versus-host reaction Health risks Hematology Hematopoietic stem cell transplantation Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cell Transplantation - mortality Hematopoietic stem cells Humans Internal Medicine Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - therapy Medicine Medicine & Public Health Middle Aged Myelodysplastic syndrome Myelodysplastic syndromes Myelodysplastic Syndromes - mortality Myelodysplastic Syndromes - therapy original-article Patients Prophylaxis Public Health Quality Retrospective Studies Stem cell transplantation Stem Cells Survival Survival Rate Thymoglobulin Transplantation, Homologous Transplants & implants Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!